Biotron Limited

Biotron Limited (Biotron) is a biotechnology company based in Sydney, Australia, NSW. The company develops novel small-molecule antiviral therapeutics targeting Hepatitis C and HIV. Biotron has identified a new class of viral proteins as targets for potential intervention and is developing novel small-molecule therapeutics that target these proteins, specifically the P7 protein of Hepatitis C and Vpu protein of HIV.

BIT225

Biotron's leading medication is BIT225. It is currently in clinical development for the treatment of both HIV and Hepatitis C, as well as the HIV/Hepatitis C co-infected population. It is thought to be the first of a new class of oral direct-acting antiviral drug for Hepatitis C that might be combined with either current treatment techniques or future classes of direct-acting antiviral therapies in development.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.